

January 20, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: AstraZeneca Pharma India Limited receives permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200 mg (Andexxa)

This is to inform that AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200 mg (Andexxa).

Through this approval, Andexanet alfa is indicated for patients treated with FXa inhibitors (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India for the specified indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you
Yours faithfully

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary